US News

Low dosage may be behind low efficacy of CureVac vaccine -study leader

Published by

By Caroline Copley BERLIN (Reuters) – The low dosage might be a key reason why CureVac’s COVID-19 vaccine reported disappointing efficacy in a pivotal late-stage trial, the scientist leading the study of the shot said on Thursday. The German biotech’s vaccine proved only 47% effective in an initial trial, far lower than those of rivals BioNTech/Pfizer and Moderna, which are also based on mRNA technology and had efficacy rates well above 90%. Peter Kremsner from the University Hospital in Tuebingen which is running the trial told Reuters the low efficacy is “very likely due to the dose”. Unlike…

Read More

Facebook Comments

Check Also

Book Reveals Putin Directly Confronted Biden Over 'He's A Killer' Remarks

Book Reveals Putin Directly Confronted Biden Over ‘He’s ...